Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

NCT04202679 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurodermatitis

Interventions

DRUG: Dupilumab SAR231893
DRUG: Placebo
DRUG: Moisturizers
DRUG: Low to medium potent topical corticosteroids
DRUG: Topical calcineurin inhibitors

Sponsor

Sanofi

Collaborators

[object Object]